碳酸镧联合Supra-HFR血滤吸附治疗维持性血液透析患者继发性甲状旁腺功能亢进的疗效观察  

Clinical efficacy of lanthanum carbonate and Supra-HFR hemofiltration adsorption in maintenance hemodialysis patients with secondary hyperparathyroidism

作　　者：冯艳翠[1] 谢辉[1] 张海红[1] 林媚[1] 刘妙燕[1] FENG Yan-cui;XIE Hui;ZHANG Hai-hong;LIN Mei;LIU Miao-yan(Department of Nephrology,Kaiping Central Hospital,Kaiping 529300,China)

机构地区：[1]广东省开平市中心医院肾内科,广东开平529300

出　　处：《广东医科大学学报》2021年第1期70-73,共4页Journal of Guangdong Medical University

摘　　要：目的观察碳酸镧联合Supra-HFR血滤吸附治疗维持性血液透析(MHD)患者继发性甲状旁腺功能亢进(SHPT)的临床疗效。方法 80例MHD合并SHPT患者随机分为实验组和对照组:实验组给予口服碳酸镧+血液透析(2次/周)+Supra-HFR血滤吸附(1次/周),对照组给予口服碳酸镧+血液透析(3次/周)。比较两组治疗后4周血钙、磷、血清全段甲状旁腺激素(iPTH)水平。结果治疗后两组血钙水平均较同组治疗前升高(P<0.01),但组间差异无统计学意义(P>0.05);血磷水平明显下降,以实验组更为显著(P<0.05)。实验组治疗后血iPTH明显降低(P<0.01),而对照组则否。结论碳酸镧联合Supra-HFR血滤吸附可有效降低SHPT患者iPTH水平,改善钙磷代谢。Objective To observe the clinical efficacy of lanthanum carbonate and Supra-HFR hemofiltration adsorption in maintenance hemodialysis(MHD) patients with secondary hyperparathyroidism(SHPT). Methods Eighty MHD patients with SHPT were randomly treated with oral lanthanum carbonate + twice weekly hemodialysis + once weekly Supra-HFR hemofiltration absorption(experimental group) or oral lanthanum carbonate + thrice weekly hemodialysis(control group). Serum levels of calcium, phosphorus, and intact parathyroid hormone(iPTH) were compared between two groups 4 weeks post-treatment. Results Serum calcium content increased(P<0.01) post-treatment in both groups without a significant difference between two groups(P>0.05). Serum phosphorus level decreased(P<0.01) post-treatment in both groups, especially in experimental group(P<0.05). Serum iPTH level reduced post-treatment in experimental group(P<0.01) but not in control group. Conclusion Combined use of lanthanum carbonate and Supra-HFR hemofiltration absorption can effectively reduce serum iPTH level and improve calcium-phosphorus metabolism in MHD patients with SHPT.

关 键 词：血滤吸附 碳酸镧 血液透析 继发性甲状旁腺功能亢进 

分 类 号：R582.1[医药卫生—内分泌] R692.5[医药卫生—内科学]